Ac 3 GalNAc-Bn or DMSO for 3 days. Cells were then collected, lysed, and one fraction was treated with neuraminidase before blotting with PNA, which recognizes Core 1 O-glycan. Actin was used as loading control (a-d) and fetuin was used as a control for neuraminidase treatment and lectin staining (e). Without neuraminidase treatment, Ac 3 GalNAc-Bn did not reveal significant PNA binding, indicating that 50 μM Ac 3 GalNAc-Bn did not inhibit addition of sialic acid to Core 1 structure. With neuraminidase treatment, Ac 3 GalNAc-Bn did not reduce PNA binding, indicating that 50 μM Ac 3 GalNAc-Bn did not block Core 1 O-glycan synthesis. Representative blots are shown (n = 2). Staining with RCA-I, SNA, and MAL-I with or without neuraminidase treatment did not differ between Ac 3 GalNAc-Bn or DMSO incubated cells, indicating that 50 μM Ac 3 GalNAc-Bn did not disrupt addition of sialic acid to N-glycan termini or biosynthesis of N-glycans. Representative blots are shown (n = 2).
a b
Comp (x6) Comp ( Supplementary Fig. 12 Fig. S15   Supplementary Fig. 15. Reproducibility of CORA. (a, b) Ac 3 GalNAc-Bn was added to HL-60 cells and Bn-O-glycans were purified, permethylated and analyzed. MALDI-MS profiles from two independent experiments are shown and nearly identical. MALDI-MS/MS experiments described in Supplementary Fig. 12 were independently performed but used same material as those used for (a) here. Ac 3 GalNAc-Bn and DMSO are off-set, but scaled to same absolute intensity for each experiment. Fig 16. Analysis of HUVEC, MKN45, and WEHI-3 O-glycans by ESI-MS. 50 μM Ac 3 GalNAcBn was incubated with (a) HUVEC, (b) MKN45, and (c) WEHI-3 cells for 3 days and Bn-O-glycans were purified and permethylated. To validate our MALDI-MS data from Fig. 3a, 4a, and 5 on a different mass spectrometry platform, we analyzed permethylated samples by ESI-MS on an Orbitrap Fusion mass spectrometer in positive ion mode with full MS1 scan. Spectrum is enlarged for 2000-2500 m/z in inset for (b). Profiles were similar from ESI-MS versus MALDI-MS. Glycans indicated were not detected in vehicle only control (not shown). Kudelka, et al, Fig. S18   Supplementary Fig. 18 . Sensitivity of CORA. (a) MDA-MB-231 and (b) MCF7 cells were seeded at the indicated cell densities, 50 μM Ac 3 GalNAc-Bn was added, and Bn-O-glycans were purified and permethylated after 3 days. A fraction of total glycans were analyzed by MALDI-MS (composition). Spectra are off-set for each seeding density and scaled relative to maximum intensity. Representative profiles are shown (n = 2). Supplementary Fig. 19 . O-glycome of murine pulmonary endothelial cells. (a-d) Tn(-) and Tn(+) murine pulmonary endothelial cells (mPECs), with or without Cosmc, respectively, were obtained from mosaic EHC-Cosmc +/mice (immortalized) or EHC-Cosmc +/y or EHC-Cosmc -/y mice (primary). Tn expression and CD31 (an endothelial marker) was analyzed by immunofluorescence for immortalized (a) and primary cells (c). Ac 3 GalNAc or DMSO was added to immortalized (b) or primary cells (d) and Bn-O-glycans were purified after 3 days, permethylated, and analyzed by MALDI.
Similar O-glycan structures were observed in immortalized and primary cells; however, relative ratios of O-glycans differed. Spectra are off-set, but scaled to same absolute intensity for each cell type (primary, immortalized) . Representative profiles are shown (n = 2). Kudelka, et al, Fig. S20   Supplementary Fig. 20 . Profiling the O-glycome of Primary Cells. Ac 3 GalNAc-Bn or DMSO was added to (a) HUVECs or (b) primary human dermal fibroblasts seeded at 12.5 × 10 4 , 5 × 10 4 , or 2.5 × 10 4 cells/well. Glycan structures and masses are omitted for clarity, but similar to those indicated in Fig. 5 and Supplementary Fig. 22 . Spectra are off-set, but scaled relative to absolute intensity for cells seeded at a given density and relative to maximum intensity across cell densities for a given cell type. Representative profiles are shown (n = 2). Order by Frequency (57 glycans by composition)
Human Dermal Fibroblasts
HUVEC (29) Wehi-3 (28 ) Dermal fibroblasts (18) Colo-205 (14 ) HEK-293 (12) LS174T-Tn(-) (12 ) MKN45 (11) HL-60 (10) Molt-4 (7 ) MDA-MB-231 (6 ) Primary mPEC (6) MCF7 (5) Imm orta li zed mPEC ( Supplementary Fig. 23 . Glycan frequency across cell lines evaluated in CORA. (a,b) Histograms were generated based on data from Supplementary Table 2 indicating number of cells lines expressing a given glycan (mass listed on x-axis) (a); glycans were reordered from glycans expressed in greatest number of cells to glycans expressed in least number of cells (b). Eight unique glycans were each observed in >5 cell lines, 17 glycans in 2 -5 cell lines, and 32 glycans in at most one cell line. (c) Cells were arranged in descending order from cells expressing most glycans to cells expressing fewest glycans. Then number of new glycans observed with evaluation of each additional cell line was determined. We have only considered non-sulfated and non-phosphorylated O-glycans in this study, in part because these modifications have not been previously reported in our 18 cell lines. Supplementary Fig. 24 . Computational model to estimate the size of the non-sulfated human cellular O-glycome. Data from CORA was input into a custom computational model generated in MATLAB that determines # of unique glycan masses (Y) observed given X number of randomly selected cells. 256 iterations were plotted for each xi = 1 to 18 and the average of all yi's were reported +/-SD. Nonlinear regression was performed to generate a best-fit line using Prism. Visually satisfactory models (Semi-log, log-log, quadratic) were compared by F test or AIC to determine best-fit. 95% prediction band was also plotted. SE of slope and Y intercept as well as R 2 are reported. This equation has no upper-limit suggesting that evaluation of more cells would on average identify more glycans. As described we use this equation to predict the size of the non-sulfated/phosphorylated human cellular O-glycome to be 376. This represents a lower limit as there are probably >200 cell types in the human body, a given cell type may express different glycans in different environments, and we have only considered the nonsulfated and non-phosphorylated O-glycans.
